{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:53:01Z","timestamp":1775620381207,"version":"3.50.1"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ovarian function suppressor (OFS) plus either tamoxifen (TAM) or aromatase inhibitor (AI) could improve the survival outcome for premenopausal hormone receptor-positive (HR+) breast cancer. However, the optimal OFS-based regimen and medication duration remain uncertain. This article aims to systematically evaluate the OFS-based adjuvant endocrine therapy for premenopausal breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched several public databases from January 1980 to November 2020. A random model was adopted in this meta-analysis. We used the hazard ratio (HR) with a 95% confidence interval (CI) for the statistical analysis of efficacy. The primary outcome measures included overall survival and disease-free survival.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 32 articles with 37,224 cases were included in this network meta-analysis. OFS+TAM improved 5-year disease-free survival (HR \u20130.09, 95% CI \u20130.16 to \u20130.01) and 5-year overall survival (HR \u20130.18, 95% CI \u20130.33 to \u20130.03) compared with TAM monotherapy. For OFS+AI, although the 5-year disease-free survival was improved (HR \u20130.18, 95% CI \u20130.29 to \u20130.08), the 5-year overall survival was not improved (HR \u20130.13, 95% CI \u20130.43 to 0.18). In subgroup analysis, both OFS+AI and OFS+TAM showed a protective effect in stage I\u2013III patients compared with stage I\u2013II patients. For the course of therapy, OFS+TAM for 2-years could achieve clinical benefit and the best course of therapy of OFS+AI still waits for further study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>OFS+TAM might be a better option than OFS+AI for premenopausal intensive adjuvant endocrine therapy. Stage III patients are more suitable for the OFS-based therapy. For the medication duration, the 2-years course of OFS+TAM could be effective. This analysis provides helpful information for selecting therapeutic regimen in intensive adjuvant endocrine therapy and identifying the target population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026949","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T13:10:56Z","timestamp":1629465056000},"page":"e26949","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Adjuvant ovarian suppression for premenopausal hormone receptor-positive breast cancer"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-2341","authenticated-orcid":false,"given":"Mengjie","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy, First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wuzhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery (Surgical Oncology), Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China"},{"name":"Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"166","DOI":"10.28991\/SciMedJ-2021-0302-8","article-title":"Epidemiologic evidence for association between a high dietary acid load and the breast cancer risk","volume":"3","author":"Ronco","year":"2021","journal-title":"SciMed J"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"77","DOI":"10.28991\/SciMedJ-2021-0302-1","article-title":"Non-mass enhancement in breast MRI: characterization with BI-RADS descriptors and ADC values","volume":"3","author":"Buchberger","year":"2021","journal-title":"SciMed J"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/bjs.1800761213","article-title":"Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer","volume":"76","author":"Robertson","year":"1989","journal-title":"Br J Surg"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jnci\/djk109","article-title":"Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial","volume":"99","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/oxfordjournals.annonc.a058837","article-title":"Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study","volume":"5","author":"Boccardo","year":"1994","journal-title":"Ann Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"05","DOI":"10.1007\/s12282-014-0563-x","article-title":"The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer","volume":"22","author":"Mukai","year":"2015","journal-title":"Breast Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e115065","DOI":"10.1371\/journal.pone.0115065","article-title":"Network meta-analysis using R: a review of currently available automated packages","volume":"9","author":"Neupane","year":"2014","journal-title":"PLoS One"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wics.1212","article-title":"The comprehensive R archive network","volume":"4","author":"Hornik","year":"2012","journal-title":"WIREs Comput Stat"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/92.11.903","article-title":"Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study","volume":"92","author":"Klijn","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2000.18.14.2718","article-title":"Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-\/perimenopausal breast cancer patients: results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial. boccardo@hp380.ist.unige.it","volume":"18","author":"Boccardo","year":"2000","journal-title":"J Clin Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial","volume":"95","author":"Castiglione-Gertsch","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1053\/ejso.2002.1280","article-title":"Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study","volume":"28","author":"Soreide","year":"2002","journal-title":"Eur J Surg Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2002.09.112","article-title":"Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5","volume":"20","author":"Jakesz","year":"2002","journal-title":"J Clin Oncol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1200\/JCO.2002.05.042","article-title":"Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study","volume":"20","author":"Jonat","year":"2002","journal-title":"J Clin Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1200\/JCO.2003.02.021","article-title":"High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin","volume":"21","author":"Pohl","year":"2003","journal-title":"J Clin Oncol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"4510","DOI":"10.1200\/JCO.2003.11.064","article-title":"Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group","volume":"21","author":"de Haes","year":"2003","journal-title":"J Clin Oncol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1200\/JCO.2005.03.0783","article-title":"Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93","volume":"24","author":"Colleoni","year":"2006","journal-title":"J Clin Oncol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0959-8049(03)00392-7","article-title":"Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer","volume":"39","author":"Kaufmann","year":"2003","journal-title":"Eur J Cancer"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1200\/JCO.2005.05.551","article-title":"Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)","volume":"23","author":"Davidson","year":"2005","journal-title":"J Clin Oncol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/annonc\/mdi085","article-title":"Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy","volume":"16","author":"Arriagada","year":"2005","journal-title":"Ann Oncol"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bjc.6602355","article-title":"A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer","volume":"92","author":"De Placido","year":"2005","journal-title":"Br J Cancer"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.ejca.2006.04.006","article-title":"CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93)","volume":"42","author":"von Minckwitz","year":"2006","journal-title":"Eur J Cancer"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/annonc\/mdl107","article-title":"Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial","volume":"17","author":"Roche","year":"2006","journal-title":"Ann Oncol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2005.12.013","article-title":"Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study","volume":"42","author":"Baum","year":"2006","journal-title":"Eur J Cancer"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/j.ejca.2007.08.012","article-title":"A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93","volume":"43","author":"Kaufmann","year":"2007","journal-title":"Eur J Cancer"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.bjc.6603947","article-title":"Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer","volume":"97","author":"Torrisi","year":"2007","journal-title":"Br J Cancer"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jnci\/djn498","article-title":"Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer","volume":"101","author":"Hackshaw","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R41-20250504","first-page":"375","article-title":"The trial of goserelin combining with endocrine therapy in premenopausal high risk breast cancer","volume":"20","author":"Wang","year":"2010","journal-title":"Chin J Cancer"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10549-010-0794-2","article-title":"Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer","volume":"123","author":"Paridaens","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10549-011-1593-0","article-title":"Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer","volume":"128","author":"Sverrisdottir","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/cncr.27818","article-title":"Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer","volume":"119","author":"Iwata","year":"2013","journal-title":"Cancer"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J Clin Oncol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ctrv.2013.12.001","article-title":"Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials","volume":"40","author":"Del Mastro","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.2174\/1381612820666140826153711","article-title":"Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance","volume":"20","author":"Kesmodel","year":"2014","journal-title":"Curr Pharm Des"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2008-0055","article-title":"Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter?","volume":"13","author":"Miller","year":"2008","journal-title":"Oncologist"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1021\/jm00173a001","article-title":"Mechanism and inhibition of cytochrome P-450 aromatase","volume":"33","author":"Cole","year":"1990","journal-title":"J Med Chem"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1210\/me.2006-0281","article-title":"Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase","volume":"21","author":"Hong","year":"2007","journal-title":"Mol Endocrinol"},{"key":"R53-20250504","first-page":"2049","article-title":"Induction of aromatase expression by aminoglutethimide, an aromatase inhibitor that is used to treat breast cancer in postmenopausal women","volume":"19","author":"Kao","year":"1998","journal-title":"Anticancer Res"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1677\/erc.0.0060149","article-title":"Breast tumor aromatase: functional role and transcriptional regulation","volume":"6","author":"Chen","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"R55-20250504","first-page":"473","article-title":"The role of ovarian suppression in premenopausal women with hormone receptor-positive early-stage breast cancer","volume":"29","author":"Jain","year":"2015","journal-title":"Oncology (Williston Park, NY)"},{"key":"R56-20250504","first-page":"CD013538","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.28991\/esj-2019-01178","article-title":"Developing an integrated genomic profile for cancer patients with the use of NGS data","volume":"3","author":"Kosvyra","year":"2019","journal-title":"Emerging Sci J"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1093\/jnci\/djg119","article-title":"Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial","volume":"95","author":"Castiglione-Gertsch","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1200\/JCO.2003.02.021","article-title":"High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin","volume":"21","author":"Pohl","year":"2003","journal-title":"J Clin Oncol"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/or.2013.2312","article-title":"Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial","volume":"29","author":"Nishimura","year":"2013","journal-title":"Oncol Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T08:00:56Z","timestamp":1746345656000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026949"}},"subtitle":["A network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":59,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026949","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"2021-01-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}